| Market Cap | 8.92B 7.69B 7.08B 6.65B 12.48B 844B 12.61B 83.68B 32.6B 413B 33.49B 32.78B 1,432B | P/E Ratio 2026 * |
159x | P/E Ratio 2027 * | 34.5x |
|---|---|---|---|---|---|
| Enterprise Value | 8.71B 7.51B 6.91B 6.49B 12.18B 823B 12.31B 81.67B 31.82B 403B 32.69B 31.99B 1,397B | EV / Sales 2026 * |
8.66x | EV / Sales 2027 * | 6.03x |
| Free-Float |
65.96% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Corcept Therapeutics
| 1 day | +0.16% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 31/12/1998 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 28/02/2021 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 31/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 31/12/1998 |
James Wilson
CHM | Chairman | 82 | 31/12/1998 |
David Mahoney
BRD | Director/Board Member | 71 | 30/06/2004 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | +13.02% | - | - | 8.92B | |
| -0.61% | -2.32% | +37.00% | +147.28% | 1,007B | |
| -0.20% | +1.30% | +49.70% | +43.64% | 567B | |
| +0.40% | -0.27% | +16.43% | +63.71% | 392B | |
| -0.80% | +1.05% | +20.91% | +18.37% | 328B | |
| -0.43% | +2.01% | +23.20% | +32.46% | 277B | |
| +0.64% | -3.71% | +20.92% | +13.67% | 275B | |
| -1.86% | +3.05% | -45.70% | -49.24% | 196B | |
| -0.77% | +0.61% | +17.82% | +52.27% | 189B | |
| +2.36% | -0.68% | +15.68% | +61.05% | 154B | |
| Average | -0.02% | +0.33% | +17.33% | +42.58% | 376.23B | |
| Weighted average by Cap. | -0.20% | -0.03% | +25.91% | +66.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.01B 867M 798M 750M 1.41B 95.12B 1.42B 9.43B 3.68B 46.58B 3.78B 3.7B 161B | 1.4B 1.21B 1.11B 1.04B 1.96B 132B 1.98B 13.13B 5.11B 64.82B 5.25B 5.14B 225B |
| Net income | 85.73M 73.88M 68.03M 63.88M 120M 8.11B 121M 804M 313M 3.97B 322M 315M 13.76B | 369M 318M 292M 275M 516M 34.85B 521M 3.46B 1.35B 17.06B 1.38B 1.35B 59.14B |
| Net Debt | -213M -184M -169M -159M -299M -20.17B -302M -2B -780M -9.88B -801M -784M -34.24B | -474M -409M -376M -353M -663M -44.83B -670M -4.45B -1.73B -21.95B -1.78B -1.74B -76.09B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
